Colistin plus meropenem combination is synergistic in vitro Aagainst extensively drug-resistant pseudomonas aeruginosa, including high-risk clones

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Montero, Maria Milagro
• dc.contributor.author Domene Ochoa, Sandra
• dc.contributor.author López-Causapé, Carla
• dc.contributor.author VanScoy, Brian
• dc.contributor.author Luque Pardos, Sònia
• dc.contributor.author Sorli Redó, M. Luisa
• dc.contributor.author Campillo Ambrós, Núria
• dc.contributor.author Padilla, Eduardo
• dc.contributor.author Prim, Núria
• dc.contributor.author Segura, Concepción
• dc.contributor.author Pomar, Virginia
• dc.contributor.author Rivera, Alba
• dc.contributor.author Grau Cerrato, Santiago
• dc.contributor.author Ambrose, Paul G.
• dc.contributor.author Oliver, Antonio
• dc.contributor.author Horcajada Gallego, Juan Pablo
• dc.date.accessioned 2020-02-13T07:22:40Z
• dc.date.issued 2019
• dc.description.abstract Background: Extensively drug-resistant (XDR) Pseudomonas aeruginosa (P. aeruginosa) and particularly P. aeruginosa high-risk clones, are of growing concern because treatment options are limited. For years, colistin monotherapy has been the only available treatment, but is well known that is not an optimal treatment. A combination of colistin with another antibiotic could be a possible therapeutic option. bjectives: This study aimed to investigate effective antibiotic combinations against 20 XDR P. aeruginosa isolates obtained in a Spanish multicentre study (2015). Methods: Forty-five checkerboards with six antipseudomonal antibiotics (amikacin, aztreonam, ceftazidime, meropenem, colistin, and ceftolozane/tazobactam) were performed to determine whether combinations were synergic or additive by fractional inhibitory concentration indices. On average, 15 different regimens were evaluated in duplicate against the three most prevalent high-risk clones (ST175, ST235, ST111) by time-kill analyses over 24h. The combination showing synergism in the three high-risk clones was validated in all studied XDR isolates. Results: In time-kill curves, the untreated control failed, as did each study regimen when administered alone. Two combinations were synergistic in the three high-risk clones that were initially studied: amikacin plus ceftazidime and colistin plus meropenem, with the second being the most effective combination. The efficacy of colistin plus meropenem was then tested in all 20 isolates. A synergistic bacterial density reduction for the duration of the study occurred in 80% of the entire XDR collection. Conclusions: These data suggest that colistin plus meropenem may be a useful combination for the treatment of infections due to XDR P. aeruginosa, including high-risk clones, which warrants evaluation in a clinical trial.
• dc.format.mimetype application/pdf
• dc.identifier.citation Montero MM, Domene Ochoa S, López-Causapé C, VanScoy B, Luque S, Sorlí L et al. Colistin plus meropenem combination is synergistic in vitro Aagainst extensively drug-resistant pseudomonas aeruginosa, including high-risk clones. J Glob Antimicrob Resist. 2019 Sep;18:37-44. DOI: 10.1016/j.jgar.2019.04.012
• dc.identifier.doi http://dx.doi.org/10.1016/j.jgar.2019.04.012
• dc.identifier.issn 2213-7165
• dc.identifier.uri http://hdl.handle.net/10230/43560
• dc.language.iso eng
• dc.publisher Elsevier
• dc.relation.ispartof Journal of Global Antimicrobial Resistance. 2019 Sep;18:37-44
• dc.rights © Elsevier http://dx.doi.org/10.1016/j.jgar.2019.04.012
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.keyword Colistin
• dc.subject.keyword Combination therapy
• dc.subject.keyword Meropenem
• dc.subject.keyword Pseudomonas aeruginosa
• dc.subject.keyword Synergy
• dc.title Colistin plus meropenem combination is synergistic in vitro Aagainst extensively drug-resistant pseudomonas aeruginosa, including high-risk clones
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion